Cholangiocarcinoma: treatment with sorafenib extended life expectancy to greater than four years.

Abstract

This case illustrates the potential benefit of using Sorafenib in locally advanced cholangiocarcinoma. This provides hope for more trials, to establish selection criteria for administration of this drug.